Impel NeuroPharma Inc. (IMPL) Announces FDA Approval of TRUDHESA for Migraine
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Harry and Meghan surprised by King Charles' letter on their status
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Qualcomm to issue warrant to Amazon for up to 25M shares
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Impel NeuroPharma Inc. (IMPL) Launches 3M Share Proposed Offering
September 7, 2021 4:01 PM EDTImpel NeuroPharma, Inc. (NASDAQ: IMPL) announced that it has commenced an underwritten public offering of 3,000,000 shares of its common stock. All of the shares of common stock are being offered by Impel. In addition, Impel intends to grant the underwriters a 30-day option to... More
Impel Neuropharma (IMPL) PT Raised to $55 at Cowen on FDA Approval
September 3, 2021 10:57 AM EDTCowen analyst Ken Cacciatore raised the price target on Impel Neuropharma (NASDAQ: IMPL) to $55.00 (from $35.00) while maintaining an Outperform rating.
The analyst commented, "The FDA has approved Trudhesa for the treatment of acute migraines with a clean label right in line with our... More
Impel NeuroPharma Inc. (IMPL) surges 59% as trading reumes on FDA approval
September 3, 2021 9:18 AM EDTImpel NeuroPharma Inc. (NASDAQ: IMPL) surges 59% as trading reumes on FDA approval
... More